Diabetes Mel l it us Model (DMM): Internal validation of a computer simulation model for type 1 and type 2 diabetes

Journal of Medical Economics

Volumn 9, Issue 42008, 2006, Pages 69-82

  Maxion Bergemann, Stefanie ^a   Walleser, Silke ^a   Müller, Elvira ^a   Dinneen, Sean f ^b   Suissa, Samy ^c   Hauner, Hans ^d   Morris, Andrew d ^e   Bergemann, Rito ^a  

^a Analytica International   (Germany)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

computer simulation model; diabetes; internal validation

Indexed keywords

AMPUTATION; ANGINA PECTORIS; ARTICLE; BLINDNESS; COMPUTER SIMULATION; CONFIDENCE INTERVAL; DATA BASE; DIABETES MELLITUS MODEL; DIABETIC FOOT; HEART FAILURE; HEART INFARCTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINA MACULA EDEMA; RETINOPATHY; STROKE; THEORETICAL MODEL; VALIDATION STUDY;

EID: 33745996106     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/200609069082     Document Type: Article

References (23)

1. Streufert S, Satish U, Barach P. Improving medical care: the use of simulation technology. Simulation & Gaming 2001; 32: 164 – 174.
2. Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, Editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press, 2002: 141 – 171.
3. Ramsey SD, McIntosh M, Etzioni R et al. Simulation modeling of outcomes and cost effectiveness. Hematology/Oncology Clinics of North America 2000; 14: 925 – 938.
4. Weinstein MC, Toy EL, Sandberg EA et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value in Health 2001; 4: 348 – 361.
5. Coyle D, Lee KM, O’Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. PharmacoEconomics 2002; 20(Suppl 1): 11 – 19.
6. Bergemann R, Suissa S, Morris A et al. A simulation model for diabetes type 1 and 2: model description and internal validation process with UKPDS, DCCT and WESDR. Diabetologia 2001; 44(Suppl 1): Abstract 114.
7. Hauner H, Maxion-Bergmann S, Muller E et al. [Disease management program (DMP) diabetes mellitus: simulation of therapeutic results of different guidelines. A new diabetes mellitus model (DMM).] Deutsche Medizinische Wochenschrift (1946) 2003; 128: 1167 – 72 [in German].
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837 – 853.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703 – 713.
10. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993; 329: 977– 986.
11. Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999; 22: 951 – 959.
12. Bergemann R, Hauner H, Morris A et al. Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mellitus Model (DMM). Journal of Medical Economics 2006; 9: 83 – 99.
13. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. PharmacoEconomics 2000; 17: 461 – 477.
14. Ahrens J, Dieter U. Extensions of Forsythe’s method for random sampling from the Normal distribution. Math Comput 1973; 27: 927 – 937.
15. James F. RANFLUX: a Fortran implementation of the high-quality pseudorandom number generator. Computer Physics Communications 1994; 79: 111 – 114.
16. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998 – 1003.
17. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801 – 1815.
18. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7 – 16.
19. Klein R, Klein BE, Moss SE et al. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999; 22: 743 – 751.
20. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Archives of Internal Medicine 1992; 152: 610 – 616.
21. Stratton I, Adler A, Neil A et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405 – 412.
22. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412 – 419.
23. Bojestig M, Arnqvist HJ, Hermansson G et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. New England Journal of Medicine 1994; 330: 15 – 18.